A Tissue-based Biomarker Risk Score for Predicting Survival in Pancreatic Ductal Adenocarcinoma

Area of Science:

• Oncology
• Biomarker Discovery
• Cancer Prognostics

Background:

• Pancreatic cancer has a poor prognosis with limited risk stratification tools.
• Accurate prognostic markers are crucial for personalized treatment in pancreatic cancer.

Purpose of the Study:

• To evaluate the prognostic significance of nine tissue biomarkers in pancreatic cancer.
• To develop a novel biomarker-based risk score for predicting patient survival.

Main Methods:

• Analyzed tumor samples from 141 pancreatic cancer patients using immunohistochemistry.
• Assessed expression of CA 19-9, CA 50, CA 242, CA 724, GDF15, MMP7, MUC2, TFF1, and THBS2.
• Developed a prognostic risk score using Lasso-Cox regression and validated with survival analysis and ROC curves.

Main Results:

• CA19-9, CA50, CA242, CA724, and THBS2 were significant predictors of survival.
• The integrated risk model, including CA19-9, CA724, THBS2, and clinical factors, stratified patients into high- and low-risk groups.
• High-risk patients showed significantly shorter median survival (14.8 vs. 36.0 months) and 5-year survival (5.9% vs. 26.0%) (p<0.001).
• The model demonstrated good predictive performance (AUC=0.704).

Conclusions:

• Identified key tissue biomarkers for pancreatic cancer survival prediction.
• Developed an integrative risk model with good discriminatory ability for patient stratification.
• The model offers a foundation for personalized risk assessment and treatment planning in pancreatic cancer, pending further validation.